These include observations on the classical and established AD biomarkers [11,12,13,14], including altered genetics (incorporating genome-wide association studies or GWAS), genetic mutations and gene modifications (including methylation and post-transcriptional modifications), end-stage neurotoxic and pathogenic metabolic products that accumulate in AD brains, such as multiple forms of tau aggregates and amyloid-beta (Aβ) aggregation species and plaques. Here, MAPT is linked to Alzheimer disease.